Literature DB >> 28663209

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.

Florian Krammer1, Adolfo García-Sastre1,2,3, Peter Palese1,3.   

Abstract

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza virus vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness. Here we discuss the characteristics of universal influenza virus vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such vaccines.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28663209      PMCID: PMC6028071          DOI: 10.1101/cshperspect.a028845

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  35 in total

Review 1.  Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.

Authors:  Catherine J Luke; Kanta Subbarao
Journal:  Expert Rev Vaccines       Date:  2014-05-23       Impact factor: 5.217

2.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.

Authors:  J C de Jong; W E Beyer; A M Palache; G F Rimmelzwaan; A D Osterhaus
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

3.  I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?

Authors:  Esther Kissling; Baltazar Nunes; Chris Robertson; Marta Valenciano; Annicka Reuss; Amparo Larrauri; Jean Marie Cohen; Beatrix Oroszi; Caterina Rizzo; Ausenda Machado; Daniela Pitigoi; Lisa Domegan; Iwona Paradowska-Stankiewicz; Udo Buchholz; Alin Gherasim; Isabelle Daviaud; Judit Krisztina Horváth; Antonino Bella; Emilia Lupulescu; Joan O Donnell; Monika Korczyńska; Alain Moren
Journal:  Euro Surveill       Date:  2016-04-21

4.  Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.

Authors:  J Castilla; I Martínez-Baz; V Martínez-Artola; G Reina; F Pozo; M García Cenoz; M Guevara; J Morán; F Irisarri; M Arriazu; E Albéniz; C Ezpeleta; A Barricarte
Journal:  Euro Surveill       Date:  2013-01-31

Review 5.  Vaccine-associated inflammatory diseases of the central nervous system: from signals to causation.

Authors:  Xuan-Hung Nguyen; Abdelhadi Saoudi; Roland S Liblau
Journal:  Curr Opin Neurol       Date:  2016-06       Impact factor: 5.710

6.  Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody.

Authors:  Ning Chai; Lee R Swem; Mike Reichelt; Haiyin Chen-Harris; Elizabeth Luis; Summer Park; Ashley Fouts; Patrick Lupardus; Thomas D Wu; Olga Li; Jacqueline McBride; Michael Lawrence; Min Xu; Man-Wah Tan
Journal:  PLoS Pathog       Date:  2016-06-28       Impact factor: 6.823

7.  H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps.

Authors:  Hang Xie; Xiu-Feng Wan; Zhiping Ye; Ewan P Plant; Yangqing Zhao; Yifei Xu; Xing Li; Courtney Finch; Nan Zhao; Toshiaki Kawano; Olga Zoueva; Meng-Jung Chiang; Xianghong Jing; Zhengshi Lin; Anding Zhang; Yanhong Zhu
Journal:  Sci Rep       Date:  2015-10-16       Impact factor: 4.379

8.  Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.

Authors:  Carole J Henry Dunand; Paul E Leon; Min Huang; Angela Choi; Veronika Chromikova; Irvin Y Ho; Gene S Tan; John Cruz; Ariana Hirsh; Nai-Ying Zheng; Caitlin E Mullarkey; Francis A Ennis; Masanori Terajima; John J Treanor; David J Topham; Kanta Subbarao; Peter Palese; Florian Krammer; Patrick C Wilson
Journal:  Cell Host Microbe       Date:  2016-06-08       Impact factor: 21.023

9.  Universal influenza vaccines: Shifting to better vaccines.

Authors:  Francesco Berlanda Scorza; Vadim Tsvetnitsky; John J Donnelly
Journal:  Vaccine       Date:  2016-03-31       Impact factor: 3.641

10.  What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins.

Authors:  Hillary A Vanderven; Fernanda Ana-Sosa-Batiz; Sinthujan Jegaskanda; Steven Rockman; Karen Laurie; Ian Barr; Weisan Chen; Bruce Wines; P Mark Hogarth; Teresa Lambe; Sarah C Gilbert; Matthew S Parsons; Stephen J Kent
Journal:  EBioMedicine       Date:  2016-04-28       Impact factor: 8.143

View more
  41 in total

1.  Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Authors:  Yao-Qing Chen; Linda Yu-Ling Lan; Min Huang; Carole Henry; Patrick C Wilson
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Authors:  Elene Clemens; Davide Angeletti; Beth C Holbrook; Masaru Kanekiyo; Matthew J Jorgensen; Barney S Graham; Jonathan Yewdell; Martha A Alexander-Miller
Journal:  JCI Insight       Date:  2020-03-12

3.  Exploring the potential public health benefits of universal influenza vaccine.

Authors:  Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown
Journal:  Hum Vaccin Immunother       Date:  2019-06-18       Impact factor: 3.452

4.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Authors:  Maya Sangesland; Larance Ronsard; Samuel W Kazer; Julia Bals; Seyhan Boyoglu-Barnum; Ashraf S Yousif; Ralston Barnes; Jared Feldman; Maricel Quirindongo-Crespo; Patrick M McTamney; Daniel Rohrer; Nils Lonberg; Bryce Chackerian; Barney S Graham; Masaru Kanekiyo; Alex K Shalek; Daniel Lingwood
Journal:  Immunity       Date:  2019-09-25       Impact factor: 31.745

Review 5.  Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Authors:  Daniel Stadlbauer; Raffael Nachbagauer; Philip Meade; Florian Krammer
Journal:  Front Med       Date:  2017-11-20       Impact factor: 4.592

Review 6.  Development of a Universal Influenza Vaccine.

Authors:  Leonardo D Estrada; Stacey Schultz-Cherry
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

7.  Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.

Authors:  Carole Henry; Anna-Karin E Palm; Henry A Utset; Min Huang; Irvin Y Ho; Nai-Ying Zheng; Theresa Fitzgerald; Karlynn E Neu; Yao-Qing Chen; Florian Krammer; John J Treanor; Andrea J Sant; David J Topham; Patrick C Wilson
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

8.  Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Authors:  Bo Ryoung Park; Jeeva Subbiah; Ki-Hye Kim; Young-Man Kwon; Judy Oh; Min-Chul Kim; Chong-Hyun Shin; Baik Lin Seong; Sang-Moo Kang
Journal:  Virology       Date:  2021-12-10       Impact factor: 3.616

9.  Defining and Manipulating B Cell Immunodominance Hierarchies to Elicit Broadly Neutralizing Antibody Responses against Influenza Virus.

Authors:  Assaf Amitai; Maya Sangesland; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; Daniel Lingwood; Arup K Chakraborty
Journal:  Cell Syst       Date:  2020-10-07       Impact factor: 10.304

10.  Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge.

Authors:  Sean A Nelson; Thamotharampillai Dileepan; Amy Rasley; Marc K Jenkins; Nicholas O Fischer; Andrea J Sant
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.